Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms

Next Previous
X
Search
Trial Profile

A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MDG 1011 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors MediGene AG

    • Most Recent Events

    • 24 Apr 2023 Results presented in the Medigene media release.
    • 24 Apr 2023 According to Medigene media release, final phase I dose escalation results from this study. The data will be presented as an e-poster (P227) at the European Society for Blood and Marrow Transplantation (EBMT) 2023 annual meeting held from 23rd-26th April.
    • 24 Apr 2023 According to a Medigene media release, data will be presented as an eposter (P227) at the European Society for Blood and Marrow Transplantation (EBMT) 2023 annual meeting, being held April 23-26, 2023, in Paris.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top